Insider trade report
Open the filing on sec.gov
Unicycive Therapeutics, Inc. (UNCY)
Nasdaq: UNCY · Pharmaceutical Preparations · Los Altos, CA · filing with the SEC since 2019
The companyfiscal 2023, as filed
Revenue$675,000-29.0%
Net income-$30.5M-69.1%
Earnings per share$-12.80-6.7%
Operating cash flow-$18.3M-16.8%
Cash$9.7M+2032.1%
Debtn/a
Shareholders’ equity-$3.8M-717.4%
Shares, diluted2,453,931+63.0%
Return on equity-87.9%
The recordfrom its filings
Filings in 202647
Newest filingOct 29 · 4
Annual reportMar 30, 2026
Quarterly reportAug 12, 2026
Next report due10-Q by Nov 14
Insider sales, 12 months$0.00
Insider buys, 12 months$0.00
Patents granted4
Filer category<br>Emerging growth company
Trailing twelve months to Jun 2026Net income -$35.2MCash from operations -$27.8Mthe four newest filed quarters added
Left: the newest annual report, with the change on the year before. Right: counted from the company's own filings with the SEC.
As filed, in USD. Nothing here is a forecast.
News
Insider holding, initial
Open the filing on sec.gov
Current report
Open the filing on sec.gov
Current report
Open the filing on sec.gov
Large holder update, amended
Open the filing on sec.gov
Large holder update, amended
Open the filing on sec.gov
Results released
Open the filing on sec.gov
Quarterly report
Open the filing on sec.gov
Large holder notice
Open the filing on sec.gov
Insider trade report, amended
Open the filing on sec.gov
Nothing of this kind is on the record for this company yet.
An outside story is shown by its headline, its source and its link only. The SI reads the page when you ask it to break one down.